1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Trimectin 10 mg/ml Solution for Injection for cattle and pigs [IE]
Euromec 10 mg/ml Solution for Injection for cattle and pigs [NL]

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains

Active substance:

Ivermectin 10 mg

Excipients:

Qualitative composition of excipients and other constituents
Glycerol
Glycerol formal

A clear, colourless to slightly yellow coloured solution.

3. CLINICAL INFORMATION

3.1 Target species

Cattle and pigs.

3.2 Indications for use for each target species

For the effective treatment and control of the following harmful parasites of cattle and pigs:

Cattle:
Gastrointestinal roundworms (adult and fourth-stage larvae):
Ostertagia spp. (including inhibited *O. ostertagi*)
Haemonochus placei
Trichostrongylus axei
Trichostrongylus colubriformis
Cooperia spp.
Bunostomum phlebotomum
Oesophagostomum radiatum
Strongyloides papillosus (adult)
Nematodirus helvetianus (adult)
N. spathiger (adult)

Lungworms (adult and fourth-stage larvae):
Dictyocaulus viviparus.

Eyeworms (adult):
Thelazia spp.

Warbles (parasitic stages):
Hypoderma bovis

H. lineatum.

Mange mites:
Psoroptes bovis
Sarcoptes scabiei var. *bovis.*

Sucking lice:
Linognathus vituli
Haematopinus eurysternus
Solenopotes capillatus.

May also be used as an aid in the control of the mange mite *Chorioptes bovis* but complete elimination may not occur.

Persistent activity
Treatment at the recommended dose rate controls re-infection with *Ostertagio* spp. and *Cooperia* spp. acquired up to 7 days after treatment and *Dictyocaulus viviparus* acquired up to 14 days after treatment.

Pigs:
Gastrointestinal roundworms (adult and fourth-stage larvae):
Ascaris suum
Hyostrongylus rubidus
Oesophagostomum spp.
Strongyloides ransomi (adult)

Lungworms:
Metastrongylus spp. (adult)

Lice:
Haematopinus suis

Mange mites:
Sarcoptes scabiei var. *suis*

3.3 Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Do not use by intramuscular or intravenous administration.

3.4 Special warnings

Unnecessary use of antiparasitics or use deviating from the instructions given in the SPC may increase the resistance selection pressure and lead to reduced efficacy. The decision to use the veterinary medicinal product should be based on confirmation of the parasitic species and burden, or of the risk of infestation based on its epidemiological features, for each individual animal or herd.

Repeated use for an extended period, particularly when using the same class of substances, increases the risk of resistance development. Within a herd, maintenance of susceptible refugia is essential to reduce that risk. Systematically applied interval-based treatment and treatment of a whole herd should be avoided. Instead, if feasible, only selected individual animals or subgroups should be treated (targeted selective treatment). This should be combined with appropriate husbandry and pasture management measures. Guidance for each specific herd should be sought from the responsible veterinarian.

Resistance to ivermectin has been reported in *Cooperia oncophora* and *Ostertagia ostertagi* in cattle. Therefore, the use of this veterinary medicinal product should be based on local (regional, farm)

epidemiological information about susceptibility of these helminth species and recommendations on how to limit further selection for resistance to anthelmintics.

The use of this veterinary medicinal product should take into account local information about susceptibility of the target parasites, where available.

It is recommended to further investigate cases of suspected resistance, using an appropriate diagnostic method (e.g. Faecal Egg Count Reduction Test (FECRT)).

Confirmed resistance should be reported to the marketing authorisation holder or to the competent authority.

3.5 Special precautions for use

Special precautions for safe use in the target species:
The veterinary medicinal product has been formulated specifically for use in cattle and pigs. It should not be used in other species as severe adverse reactions, including fatalities in dogs, may occur.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Take care to avoid self-administration: the veterinary medicinal product may cause local irritation and/or pain at the site of injection.
Direct contact of the veterinary medicinal product with the skin should be kept to a minimum.
Do not eat, drink or smoke while handling the veterinary medicinal product.
Wash hands after use.

Special precautions for the protection of the environment:
See section 5.5.

Other precautions:
When using the 250 ml and 500 ml pack sizes, use only automatic syringe equipment. For the 50 ml pack size, use of a multiple dose syringe is recommended. To refill the syringe, use of a draw off needle is recommended to avoid excessive broaching of the stopper.

3.6 Adverse events

Cattle:

Undetermined frequency (cannot be estimated from the available data):	Discomfort[1] Injection site swelling[1]

[1]Transitory.

Pigs:

Undetermined frequency (cannot be estimated from the available data):	Injection site pain[1]

[1]Mild and transient.

All these reactions disappeared without treatment.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing

authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy:
The veterinary medicinal product can be used in beef cows and pigs during pregnancy.

Lactation:
Do not use in dairy cows producing milk for human consumption
Do not use in non-lactating dairy cows within 60 days of calving. The veterinary medicinal product can be used in sows at any stage of lactation.

Fertility:
Fertility is not affected by administration of the veterinary medicinal product.

3.8 Interaction with other medicinal products and other forms of interaction

The veterinary medicinal product can be used concurrently without adverse effects with foot and mouth disease vaccine or clostridial vaccine, given at separate injection sites.

3.9 Administration routes and dosage

Subcutaneous use.

Each ml contains 10 mg of ivermectin sufficient to treat 50 kg of bodyweight of cattle and 33 kg of bodyweight of pigs. The volume administered per injection site should not exceed 10 ml. The injection may be given with any standard automatic or single-dose or hypodermic syringe. Use of 17 gauge x ½ inch needle is suggested. Replace with a fresh sterile needle after every 10 to 12 animals. Injection of wet or dirty animals is not recommended. If using a single-dose hypodermic syringe, use a separate sterile needle to withdraw the veterinary medicinal product from the container.

Cattle:
The veterinary medicinal product should be given only by subcutaneous injection at the recommended dosage level of 200 mcg ivermectin per kg bodyweight under the loose skin in front of, or behind, the shoulder in cattle. This is equivalent to 1 ml per 50 kg bodyweight.

Pigs:
In pigs, the recommended dosage level is 300 mcg ivermectin per kg bodyweight. This is equivalent to 1 ml per 33 kg bodyweight. The recommended route of administration is by subcutaneous injection into the neck.

In young pigs, especially those below 16 kg for which less than 0.5 ml of veterinary medicinal product is indicated, dosing accuracy is important. The use of a syringe that can accurately deliver as little as 0.1 ml is recommended.

Underdosing could result in ineffective use and may favour resistance development.

To ensure a correct dosage, body weight should be determined as accurately as possible. If animals are to be treated collectively, reasonably homogenous groups should be set up, and all animals of a group should be dosed at the rate corresponding to the heaviest one.

Accuracy of the dosing device should be thoroughly checked.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Cattle:

Single doses of 4.0 mg ivermectin per kg (20 x the use level) given subcutaneously resulted in ataxia and depression.

Pigs:
A dose of 30 mg ivermectin per kg (100 x the recommended dose of 0.3 mg per kg) injected subcutaneously to pigs caused lethargy, ataxia, bilateral mydriasis, intermittent tremors, laboured breathing and lateral recumbency.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Cattle:
Meat and offal: 49 days.
Do not use in lactating cows producing milk for human consumption. Do not use in non-lactating dairy cows including pregnant dairy heifers within 60 days of calving.

Pigs:
Meat and offal: 28 days.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QP54AA01

4.2 Pharmacodynamics

Ivermectin is a member of the macrocyclic lactone class of endectocides which have a unique mode of action. Compounds of the class bind selectively and with high affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve and muscle cells. This leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarization of the nerve or muscle cell, resulting in paralysis and death of the parasite. Compounds of this class may also interact with other ligand-gated chloride channels, such as those gated by the neurotransmitter gamma-aminobutyric acid (GABA).

The margin of safety for compounds of this class is attributable to the fact that mammals do not have glutamate-gates chloride channels, the macrocyclic lactones have a low affinity for other mammalian ligand-gated chloride channels and they do not readily cross the blood-brain barrier.

4.3 Pharmacokinetics

Maximum plasma concentration:
Cattle:
At a dose level of 0.2 mg ivermectin per kg a mean Cmax of 30.43 ng/ml is reached at a mean Tmax of 131 hours and the mean half-life in plasma is 142.39 hours.. It is also established that ivermectin is carried mainly in the plasma (80 %). This distribution between plasma and blood cells remains relatively constant.

Pigs:
In pigs, at a dose level of 0.3 mg ivermectin per kg bodyweight, a mean Cmax of 6.87 ng/ml was reached at a mean Tmax of 86.75 hours, and the mean elimination half-life was 133.56 hours and the drug persisted in plasma for up to 28 days.

Excretion: length of time and route
Cattle:
Only about 1-2 % is excreted in the urine the remainder is excreted in the faeces, approximately 60% of which is excreted as unaltered drug. The remainder is excreted as metabolites or degradation products.

Pigs:
Biliary excretion is also the major route of ivermectin excretion in pigs.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

None known.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Shelf life after first opening the immediate packaging: 28 days.

5.3 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

5.4 Nature and composition of immediate packaging

Multidose polyethylene bottles of 50 ml, 250 ml and 500 ml sealed with bromobutyl seals and aluminium overseals.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

The veterinary medicinal product should not enter water courses as ivermectin may be dangerous for fish and other aquatic organisms.

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

7. MARKETING AUTHORISATION NUMBER(S)

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: DD/MM/YYYY.

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

DD/MM/YYYY

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).